Our recent research has found MDS/AML patient-derived MSCs are phenotypically and functionally remodeled by myeloid cells and present a various glycosylation pattern, specifically a low bisecting GlcNAc modification, to modulate MCAM on stromal and affect proliferation of MDS/AML clonal cells [39]. This evidence concerns the gene MCAM and myelodysplastic syndrome.